1. Home
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Peripheral T cell Lymphoma - Epidemiology Forecast - 2032

Peripheral T cell Lymphoma - Epidemiology Forecast - 2032

  • September 2022
  • 117 pages
  • ID: 6321457
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

" Peripheral T-cell Lymphoma - Epidemiology Forecast– 2032” report delivers an in-depth understanding of the PTCL, historical and forecasted epidemiology as well as the PTCL market trends in the United States, the EU-5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Geography Covered
• The United States
• The EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2019-2032

Peripheral T-cell Lymphoma Disease Understanding and Treatment Algorithm

Peripheral T-cell Lymphoma Overview
Peripheral T-cell lymphomas (PTCLs) are an uncommon and heterogeneous group of clinically aggressive types of non-Hodgkin lymphoma (NHL) that develop in mature white blood cells called “T cells” and “natural killer (NK) cells.” It is PTCL’s origin in the lymphatic system that gave it the name peripheral T-cell lymphoma. In the case of PTCL, the term “peripheral” does not refer to the extremities, but identifies PTCL as cancer that arises in the lymphoid tissues outside of the bone marrow such as lymph nodes, spleen, gastrointestinal tract, and skin.
Signs and symptoms of PTCL include asymptomatic lymphadenopathy, Fever, night sweats, poor appetite, and weight loss include fatigue, painless swelling in the neck, armpit or groin (due to an enlarged lymph node). Different staging systems have been proposed for PTCLs.
Peripheral T-cell Lymphoma Diagnosis
The cells in many subtypes of PTCLs look alike; therefore, making an accurate diagnosis may require the use of additional diagnostic tests, including blood tests, CT (computerized axial tomography), PET (positron emission tomography) scans, MRI (magnetic resonance imaging), and bone marrow biopsy.

Peripheral T-cell Lymphoma Treatment
Currently, newly diagnosed PTCL patients are usually treated with anthracycline-based chemotherapy regimens. For most subtypes of PTCL, the initial treatment is typically a combination chemotherapy regimen, such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone), or other multidrug regimens. Patients with relapsed disease are usually treated with combination chemotherapy such as ICE (ifosfamide, carboplatin, and etoposide) or other combination regimens, followed by stem cell transplantation. Treatment for PTCL aims to cure and includes the use of combination chemotherapy regimens – typically CHOP based chemotherapy or EPOCH, localized radiotherapy, stem cell transplants and steroid therapy. Other drugs now approved for relapsed T-cell lymphoma include BELEODAQ (belinostat), ADCETRIS (brentuximab vedotin), POTELIGEO (mogamulizumab), Mundesine (Forodesine Hydrochloride), HIYASTA, DARVIAS, and Others.

Peripheral T-cell Lymphoma Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total incident population of PTCL, stage-specific Incident Cases of PTCL, and subtype-specific Incident cases of PTCL in the 7MM market covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Key Findings
This section provides glimpse of the PTCL epidemiology in the 7MM

Country Wise- Peripheral T-cell Lymphoma Epidemiology
• The epidemiology segment also provides the PTCL epidemiology data and findings across the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
• The total incident population of PTCL in the 7MM comprised of 18,027 cases in 2021 and are projected to increase during the forecast period.
• The total incident population of PTCL in the United States is 6,366 in 2021.
• The Japan contributed to the largest incident population of PTCL, accounting for ~ 37% of the 7MM in 2021.
• Among the EU-5 countries, Germany accounted for the highest number of PTCL cases, followed by France, whereas Spain accounted for the lowest cases in 2021.
• In Japan, the total incident population of PTCL was 6,637 in 2021 and is anticipated to rise during the forecast period.
• The major types of PTCL include Peripheral T-cell lymphoma (NOS), Anaplastic Large-Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL) and others. In 2021, the incident population of NOS, ALCL, and AITL in the United States were, 1,998, 1,643, and 1,438, cases.

Scope of the Report
• The report covers the descriptive overview of PTCL, explaining its causes, signs and symptoms, pathogenesis and diagnosis.
• Comprehensive insight has been provided into the PTCL epidemiology and treatment.
• The report provides insight about the historical and forecasted patient pool of PTCL in seven major markets covering the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• A detailed review of PTCL epidemiology forecast is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding epidemiological trends.

Report Highlights
• In the coming years, PTCL market is set to change due emerging therapies in the pipeline, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence PTCL R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• As per the analysis the major types of PTCL include Peripheral T-cell lymphoma-NOS, Anaplastic Large-Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL), Nasal NK/T-cell lymphoma, Enteropathy-type intestinal TCL, Hepatosplenic TCL and others.
• The report also encompasses other major segments, i.e. total incident population of PTCL, stage-specific Incident Cases of PTCL, and subtype-specific Incident cases of PTCL.

PTCL Report Insights

PTCL Report Insights
• Patient Population
• Eleven Years Forecast
• 7MM Coverage
• PTCL Epidemiology Segmentation

Key Questions

Epidemiology Insights:
• What is the disease risk, burden and unmet needs of PTCL?
• What is the historical PTCL patient pool in the United States, the EU-5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of PTCL at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to PTCL?
• Out of the above-mentioned countries, which country would have the highest incident population of PTCL during the study period (2019–2032)?
• At what CAGR the population is expected to grow across the 7MM during the study period (2019–2032)?

Reasons to buy
• The report will help in developing business strategies by understanding trends shaping and driving the PTCL.
• To understand the future market competition in the PTCL market and Insightful review of the SWOT analysis of PTCL.
• Organize sales and marketing efforts by identifying the best opportunities for PTCL in the US, the EU-5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for PTCL market.
• To understand the future market competition in the PTCL market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on